CONTACT

TRANSFORMING LIVES

THROUGH REGENERATIVE EXOSOME THERAPIES

DISCOVER

INTENT Biologics is dedicated to developing innovative, first-in-class exosome-based therapeutics designed to transform the treatment landscape for standards of care in inflammation and immunology. 

THE SCIENCE

INTENT’s groundbreaking therapies harness the regenerative power of exosomes—small biological vesicles naturally released by cells—to promote rapid tissue healing and regulate immune responses. Based on over two decades of research at Mayo Clinic and advanced biomanufacturing techniques developed by RION, our proprietary exosome technology represents a significant breakthrough in the treatment of chronic wounds.

Learn More About Our Science

INTENT’s lead therapeutic candidate, PEP Biologic™ (Purified Exosome Product), is a topical biologic that delivers hundreds of billions of regenerative exosomes directly to the site of injury or inflammation. With proven effectiveness in clinical studies, PEP Biologic™ offers a unique solution for conditions currently underserved by traditional therapies, including: biomanufacturing techniques developed by RION, our proprietary exosome technology represents a significant breakthrough in the treatment of chronic wounds.

Advanced Tissue Regeneration

Diabetic Foot Ulcers


Every 3 minutes in the US…
there is an amputation caused
by a Diabetic Foot Ulcer, ~200k
amputation per year.

Chronic Radiation Ulcers


Cutaneous radiation injuries
occur in ~95% of patients that
undergo radiotherapy
treatment.

Pressure Ulcers


Cause ~500k additional
hospital stays per year

Surgical Wounds


There is an ~15%-50% rate in
wound dehiscence

Venous Leg Ulcers


~13% of patients result
in amputations

No Option Wounds


Chronic wounds that have
failed all standards of care and
pose a life-threatening disease
or loss of limb

Diabetic Foot Ulcers


Every 3 minutes in the
US…there is an
amputation caused by a Diabetic Foot Ulcer, ~200k
amputation per year.

Chronic Radiation Ulcers


Cutaneous radiation
injuries occur in ~95% of
patients that undergo
radiotherapy treatment.

Pressure Ulcers


Cause ~500k additional
hospital stays per year

Surgical Wounds


There is an ~15%-50%
rate in wound dehiscence

Venous Leg Ulcers


~13% of patients result in
amputations

No Option Wounds


Chronic wounds that have
failed all standards of care
and pose a life-threatening
disease or loss of limb
Explore Our Advanced Tissue Regeneration Pipeline
Exterior of RION’s state-of-the-art biomanufacturing facility, supporting INTENT Biologics’ regenerative exosome production.

LEADERSHIP

Our headquarters in Rochester, Minnesota, host a leadership team with decades of experience from top pharmaceutical and biotechnology companies—guided by esteemed scientific and clinical advisors from Mayo Clinic—to ensure strategic direction and uphold the highest scientific standards in all we do.

Meet Our Team

Stay updated on our latest clinical advancements, partnerships, and company milestones.

NEWS


LEARN MORE

PUBLICATIONS


LEARN MORE
White molecular network representing exosome signaling pathways used in INTENT Biologics’ therapeutic platform.

INTENT

Instagram Linkedin

Address:
202 4th STREET STE 480 ROCHESTER, MN 55902

COMPANY

LEADERSHIP
CAREERS
CONTACT US

OUR SCIENCE

SCIENCE & TECHNOLOGY
PRODUCT PIPELINE

Privacy Policy
© INTENT 2025 powered by SocialStrategy1

Chris Paradise, Ph.D.
Vice President Research & Development

Dr. Chris Paradise serves as Vice President of RION’s Research and Development team. He holds a PhD in Molecular Pharmacology and Regenerative Medicine from the Mayo Clinic in Rochester, MN. Before joining Rion, Chris’s research efforts focused on engineering adult stem cells and evaluating their utility as a therapeutic strategy for tissue regeneration. His work in the Regenerative Medicine space and has been recognized by prominent international societies and has resulted in over forty peer-reviewed publications.

Chris contributes in-depth technical knowledge of stem cell biology and tissue regeneration to RION’s Research and Development team and continues to leverage this expertise to advance RION’s development of extracellular vesicle-based platforms. He is driven by a desire to translate laboratory innovation into clinical-grade therapies that improve the lives of patients.

Scott McCrea, MBA
Senior Vice President of Business Development

Scott brings over 23 years of business development and commercial experience across pharmaceutical, medical device, and cosmeceutical sectors. He has extensive experience in evaluating and commercializing medical dermatology, medical aesthetics, and consumer skincare products. Scott has a deep understanding of asset valuation and negotiation strategy that led to multiple acquisitions and licensing opportunities during his career.

Most recently, Scott was responsible for developing commercial aesthetics partnering opportunities as Director of Commericla Development for Aesthetics North America at Galderma, the wold’s largest independent global dermatology company (private equity owned).

Scott holds a Master of Business Administration from the University of Houston – C.T. Bauer College of Business and a bachelor’s degree in industrial distribution from Texas A&M University.

Jahan Jowharchi, MBA
Chief Technology Officer

Mr. Jowharchi has more than 30 years of experience in the life science industry in the area of Technical Operations. He has overseen clinical and commercial product development in engineering, operations management, and quality systems specifically in small molecules, biologics, and antibody drug conjugates with particular focus on oncology, regenerative medicine, and immunology. He has extensive experience in product life cycle management from development to clinical and commercial manufacturing, product launches as well as in support of post marketing surveillance and pharmacovigilance. Before joining RION, he supervised the contract research, development, and manufacturing organization for start-ups such as Raptor Pharmaceuticals, and Heron Therapeutics, and he served in management and leadership positions at biopharmaceutical companies such as Genentech and Novo Nordisk. He also managed a number of consulting firms and divisions to support big pharma and start-ups in the areas of facilities design, systems engineering, and operational readiness. Mr. Jowharchi holds a B.S. in mechanical engineering from the University of Massachusetts Amherst and an executive MBA from Saint Mary’s College in California.

Maureen Merrifield Ph.D.
Chief Regulatory Officer

Dr. Merrifield serves as Chief Regulatory Officer at RION. She brings more than 15 years of experience in the pharmaceutical industry to RION. She has led the regulatory strategy and submissions for products from discovery to commercialization, with significant expertise in cell and gene therapy products, monoclonal antibodies, vaccines, and protein therapies. She has regulatory expertise in Chemistry, Manufacturing, and and Controls (CMC), including non-clinical and clinical aspects of pharmaceutical development. She has been the lead of global pharmaceutical teams consisting of clinical, preclinical, CMC, statistician, and pharmacovigilance staff to advance therapeutic products through the development stages. Prior to RION, she has held the following positions: Vice President, Clinical and Regulatory Affairs at Pharmatech Associates; Director of Regulatory and Strategic Development at Clinipace Worldwide; Director of Regulatory Affairs at Bellicum Pharaceuticals; Regulatory and Affairs Project Manager at Sabin Vaccine Institute; and senior scientific roles at Sanofi and GSK. She earned both a Ph.D. and B.S. in chemistry from Western University.

Charlie Farrahar
Chief Financial Officer

Mr. Farrahar is Chief Financial Officer (CFO) at Rion and a Certified Public Accountant with more than 30 years of managerial finance, administration, human resources, investor relations, and risk management experience in the public, private, and non-profit sectors. In addition to his work at RION, Mr. Farrahar serves as CFO for several small biotech startups in various stages of development. Prior to Rion, he was CFO of Medovex Corp (now H-CYTE), a public medical biosciences company focused in the field of regenerative medicine. Before Medovex, Mr. Farrahar served as CFO and Director of Human Resources at a private governmental assistance startup, where he assisted with the sale of that company to a private equity group after it had grown into a multi-state operation with more than 400 employees.

Atta Behfar, M.D., Ph.D.
Chief Medical Officer

Dr. Behfar is the Russ and Kathy Van Cleve Professor of Regenerative Medicine at Mayo Clinic. His work has led to the development of several regenerative technologies, including cardiopoietic stem cells, which completed phase 2 and 3 trials in Europe. Over the last 15 years, Dr. Behfar has focused on the design of novel exosomes for delivery of critical signals essential to facilitate cell-free endogenous repair. Discovery of regenerative platelet-derived exosomes serve as the basis for Rion with an eye towards developing technological platforms that fundamentally change the approach to regenerative medicine by delivering low cost and off-the-shelf therapies for broad array of medical applications. In addition to being cofounder of Rion, he is Director of Van Cleve Cardiac Regenerative Medicine Program at Mayo Clinic, where he specializes in heart transplant and invasive cardiac procedures. Previously, Dr. Behfar was Director of Research at Cardio3 BioSciences, which was acquired by Celyad Oncology, after which he served as Special Scientific Advisor. Dr. Behfar holds an M.D. from the Mayo Clinic School of Medicine and a Ph.D. in stem cell biology and molecular pharmacology and therapeutics from the Mayo Clinic Graduate School of Biomedical Sciences. He earned his undergraduate degree is in biochemistry and mathematics from Marquette University.

Suneet Varma, MBA
Chief Executive Officer

Suneet Varma was recently Global and U.S. President, Oncology. During his tenure, Pfizer rose to become the third largest oncology company in the USA in 2024 with an industry- leading portfolio of 25+ approved medicines across more than 40 indications. Before leading Oncology, Suneet served as Global President of Rare Diseases, one of Pfizer’s fastest growing, high science units, which included a targeted gene therapy program.

Prior to that role, Suneet was the charter Global President of the Hospital Unit focused on both primary and alternative patient sites of care and therapeutic areas such as Anti-Infectives, Blood Management, Pain & Anesthesia amongst a dozen others. As part of this complex portfolio of ~300 treatments, approximately 50 medicines were also on the WHO essential medicines list. Further, he also over saw the company’s CDMO, Pfizer CentreOne and DoD unit, Meridian Medical Technologies, in this role.